We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,202.00
Bid: 12,202.00
Ask: 12,206.00
Change: 140.00 (1.16%)
Spread: 4.00 (0.033%)
Open: 12,194.00
High: 12,266.00
Low: 12,054.00
Prev. Close: 12,062.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK EXECUTIVE CHANGE SUMMARY: Wizz Poaches From easyJet; New Cenkos CEO

Wed, 09th Dec 2020 16:08

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Wednesday and not separately reported by Alliance News:

----------

Wizz Air Holdings PLC - Budapest-based budget airline - Hires Robert Carey as president, starting June 14 next year, to oversee operations and commercial functions. Carey has been chief commercial & strategy officer for rival carrier easyJet PLC since 2017, having started at America West Airlines followed by Delta Airlines and a 10-year stint at McKinsey & Co. Wizz also hires Michael Delehant as executive vice president and chief operations officer, reporting to Carey. Delehant joins from Vueling, the Spanish low-cost airline owned by International Consolidated Airlines Group SA, where he has been chief strategy & network officer. He starts at Wizz on April 1.

----------

Cenkos Securities PLC - London-based stock broker and company advisor - Jim Durkin will retire as chief executive in March of next year, after having returned to Cenkos in 2019. That was a difficult time for UK stockbrokers, Cenkos notes, and Durkin "kept the company profitable, led the restructuring of the board and further strengthened governance". Julian Morse, an executive director and head of the Growth Companies Team, will replace Durkin as CEO. Cenkos says Morse is a founding member of the Growth Companies Team and has led it since 2016. Cenkos also promotes Jeremy Osler, co-head of Corporate Finance & general counsel, to the board as an executive director. Osler joined Cenkos in 2016.

----------

London Stock Exchange Group PLC - trading and clearing operator and index calculator - Proposes Martin Brand, Erin Brown and Douglas Steenland as board directors. The appointments are part of LSEG's acquisition of market data and trading platform provider Refinitiv, following which the shareholders of Refinitiv will have the right to nominate three non-executive directors for as long as they continue to hold at least 25% of LSEG. Brand and Steenland will represent Blackstone, and Brown will represent Thomson Reuters. Brand is a senior managing director and co-head of US Acquisitions for Blackstone's Private Equity Group. Steenland is a a senior adviser to the Blackstone Private Equity Group. Brown is head of Finance for the Thomson Reuters Corporates segment. LSEG expects the Refinitiv acquisition to complete in the first quarter of next year.

----------

Aviva PLC - London-based life and general insurer - Hires Pippa Lambert as independent non-executive director, starting January 1. Lambert was global head of Human Resources at Deutsche Bank AG and before that head of Reward at Royal Bank of Scotland.

----------

OptiBiotix Health PLC - York, England-based developer of compounds to treat obesity, high cholesterol, diabetes and skincare - Hires Christopher Brinsmead as director. Brinsmead was president of AstraZeneca UK & Ireland, part of AstraZeneca PLC, until 2010 and before that president of the Association of the British Pharamaceutical Industry.

----------

Network International Holdings PLC - Middle East-focused payment solutions provider - Hires Diane Radley and Monique Shivanandan as independent non-executive directors, starting January 1. Radley led the Transaction Services Group at PwC South Africa. She also was CEO of Old Mutual Investment Group from 2011 to 2016, having been finance director prior to that. Shivanandan is chief information officer at property and casualty insurance firm Chubb Ltd and also a non-executive director for JP Morgan Securities in the UK.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more
2 Jan 2024 11:00

Weight-loss drugs: Who, and what, are they good for?

Jan 2 (Reuters) - Powerful weight-loss medicines like Novo Nordisk's Wegovy leapt into public view in 2023, from social media to doctors' offices and cocktail parties, offering a new way to address record obesity rates.

Read more
2 Jan 2024 11:00

What other health conditions might weight-loss drugs treat?

Jan 2 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.

Read more
2 Jan 2024 08:48

LONDON MARKET OPEN: New Year begins largely green amid slew of PMIs

(Alliance News) - Stock prices in London opened mostly up on Tuesday, the first day of trading in 2024, reacting to slightly improved factory activity in China, with more manufacturing PMIs from major economies due.

Read more
2 Jan 2024 08:26

AstraZeneca and Sanofi received approval in China for RSV antibody

(Alliance News) - AstraZeneca PLC and Sanofi SA's long-acting monoclonal antibody Beyfortus received approval for use in China to prevent respiratory syncytial virus disease, Astra said on Tuesday.

Read more
2 Jan 2024 07:57

LONDON BRIEFING: AstraZeneca, Sanofi's RSV treatment approved in China

(Alliance News) - Stock prices in London are expected to open higher on Tuesday, reacting to a slight expansion in manufacturing activity in China and ahead of a slew of manufacturing PMI data including for the UK.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.